Gaush Meditech (HKSE:02407) Capex-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Gaush Meditech's Capital Expenditure for the six months ended in Dec. 2023 was HK$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Gaush Meditech Capex-to-Revenue Historical Data

The historical data trend for Gaush Meditech's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech Capex-to-Revenue Chart

Gaush Meditech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

0.02

0.04

0.03

Gaush Meditech Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial			0.03	0.03	0.05	-	-

Competitive Comparison of Gaush Meditech's Capex-to-Revenue

For the Medical Devices subindustry, Gaush Meditech's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gaush Meditech's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gaush Meditech's Capex-to-Revenue falls into.

Gaush Meditech Capex-to-Revenue Calculation

Gaush Meditech's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-49.874)	/	1538.113
	=	0.03

Gaush Meditech's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Gaush Meditech (HKSE:02407) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Gaush Meditech Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gaush Meditech (HKSE:02407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

F7Y:Germany

Address

No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN

Website

https://www.gaush.com

Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Gao Tieta	2201 Interest of corporation controlled by you
Gaush Holding Ltd	2101 Beneficial owner
Cuprite Gem Investments Ltd	2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd.	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p.	2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p.	2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p.	2201 Interest of corporation controlled by you

Gaush Meditech (HKSE:02407) Headlines

No Headlines